Literature DB >> 27335096

Brain atrophy measurements should be used to guide therapy monitoring in MS - NO.

Frederik Barkhof1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27335096     DOI： 10.1177/1352458516649452

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  9 in total

Review 1.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

Review 2.  Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Authors:  Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2018-01-12       Impact factor: 42.937

3.  Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.

Authors:  Roland Opfer; Ann-Christin Ostwaldt; Christine Walker-Egger; Praveena Manogaran; Maria Pia Sormani; Nicola De Stefano; Sven Schippling
Journal:  J Neurol       Date:  2018-03-16       Impact factor: 4.849

Review 4.  Current concepts in multiple sclerosis therapy.

Authors:  Leslie Sedal; Antony Winkel; Joshua Laing; Lai Yin Law; Elizabeth McDonald
Journal:  Degener Neurol Neuromuscul Dis       Date:  2017-09-28

5.  Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?

Authors:  H N Beadnall; C Wang; W Van Hecke; A Ribbens; T Billiet; M H Barnett
Journal:  Ther Adv Neurol Disord       Date:  2019-01-25       Impact factor: 6.570

6.  Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.

Authors:  Roland Opfer; Julia Krüger; Lothar Spies; Marco Hamann; Carla A Wicki; Hagen H Kitzler; Carola Gocke; Diego Silva; Sven Schippling
Journal:  Neuroimage Clin       Date:  2020-10-27       Impact factor: 4.881

7.  Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Authors:  Arman Eshaghi; Ferran Prados; Wallace J Brownlee; Daniel R Altmann; Carmen Tur; M Jorge Cardoso; Floriana De Angelis; Steven H van de Pavert; Niamh Cawley; Nicola De Stefano; M Laura Stromillo; Marco Battaglini; Serena Ruggieri; Claudio Gasperini; Massimo Filippi; Maria A Rocca; Alex Rovira; Jaume Sastre-Garriga; Hugo Vrenken; Cyra E Leurs; Joep Killestein; Lukas Pirpamer; Christian Enzinger; Sebastien Ourselin; Claudia A M Gandini Wheeler-Kingshott; Declan Chard; Alan J Thompson; Daniel C Alexander; Frederik Barkhof; Olga Ciccarelli
Journal:  Ann Neurol       Date:  2018-02-06       Impact factor: 10.422

Review 8.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014

Review 9.  Predictive MRI Biomarkers in MS-A Critical Review.

Authors:  Vlad Eugen Tiu; Iulian Enache; Cristina Aura Panea; Cristina Tiu; Bogdan Ovidiu Popescu
Journal:  Medicina (Kaunas)       Date:  2022-03-03       Impact factor: 2.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.